First Parkinson’s Patient Dosed in Unixell Stem Cell Therapy Study

Unixell Biotechnology has dosed its first Parkinson’s disease patient in a clinical study of its stem cell therapy candidate, UX-DA001.

According to a press release from Unixell, a surgeon at Ruijin Hospital in Shanghai successfully injected the experimental medication directly into a patient’s brain. UX-DA001 is derived from patients’ own induced pluripotent stem cells (iPSCs) and is designed to replace damaged brain cells and alleviate symptoms.

Preliminary data suggest the treatment was safe and demonstrated signs of efficacy.